Welcome!

News Feed Item

Low T Center Comments On The Pending AndroGel Lawsuits Regarding The Safety Of Testosterone Replacement

SOUTHLAKE, Texas, Feb. 13, 2014 /PRNewswire/ -- A number of people have asked how the recent FDA inquiries into testosterone therapy, and the related lawsuits brought by AndroGel patients, effect Low T Center.  "The answer is that they don't really relate to the medicine we practice at Low T Center," says Dr. William Reilly, M.D., Executive Director of the physician practice group treating patients in Low T Centers.  "We are excited about the FDA's inquiry into alternative testosterone delivery models," says Reilly.  "Physicians have been administering testosterone injections in cases of medical necessity since the 1950's.  Clinical research places the therapeutic benefits of testosterone replacement therapy beyond question, in cases where the treatment is medically appropriate and properly managed.  The key, like any treatment," explains Reilly, "is to maintain effective protocols and closely monitor the patient's results, all in conformance with good medical practice."

(Logo: http://photos.prnewswire.com/prnh/20140213/DA65138LOGO)

Testosterone replacement therapy is the practice of replacing the body's hormone deficits with a medically normal level of testosterone.  Generally, there are two types of therapeutic alternatives.  The most established form of treatment is injection therapy.  However, gels and topical treatments (like AndroGel) have come into vogue in the past couple of years.  Recently the FDA announced that it was investigating gels and topicals after a study linked their use to increased incidence of heart attacks. 

"Gels and topical treatments rely on the patient to treat themselves, and rest on the concept of theoretical absorption rates, which may or may not play out in real life practice," warns Reilly, who trained at the Cleveland Clinic, and has been in medical practice for over thirty years.  Inconsistent absorption rates, and the dangers of self-administered treatments can cause inconsistent results, or abnormally elevated levels of testosterone, causing Reilly to shun their use.  Reilly also cautions against ongoing treatment without proper medical monitoring.  "We regularly advise patients against the use of gels and topicals.  Our treatment protocol at Low T Center involves a closely monitored regimen of injection therapy.  Basically, if you have certain symptoms corroborated by a clinically low level of testosterone, we will bring you up to normal and appropriately monitor your blood levels to ensure consistent levels." 

Low testosterone levels can lead to fatigue, inability to concentrate, as well as other symptoms.  "This is not normal aging," says Reilly, who is trained in age management medicine, and is himself a testosterone replacement patient.  "Our patients range in age from their mid-thirties to late fifties.  Before they received treatment, they were suffering,  Now, many lead normal lives." 

The AndroGel lawsuits, filed in US District Court in Illinois, each allege that a particular patient was prescribed AndroGel, when the patient did not have clinically low levels of testosterone.  The lawsuits allege a causal connection between the improper use of AndroGel and heart attacks or strokes suffered by the patient.  Rather than sue the prescribing physician, the plaintiffs in the lawsuits have sued the manufacturer of AndroGel.  They cite a recent study which attempts to correlate high testosterone levels with heart conditions.

"Testosterone replacement therapy is a serious medical treatment for a serious medical condition.  Our number one complaint is, 'You will not treat me,'" continues Reilly.  "Roughly one-half of the men who come in are not candidates for treatment under our protocol."  According to Reilly, this fact differentiates Low T Center patients from the patients involved in the lawsuits and the research study that prompted the FDA investigation.  "Generally, the patients involved in the study were given a prescription for testosterone and told to treat themselves.  There was inadequate documentation as to whether these men actually suffered from low testosterone (also called hypogonadism), and many were in their sixties and seventies with pre-existing heart conditions.  These individuals would not be candidates for treatment under Low T Center protocol," Reilly explains.  "Our protocol requires screening for contraindications, symptoms, and verification by comprehensive laboratory testing." 

Low T Center has an experience base of over 500,000 patient visits.  Dr. Reilly opines, "While testosterone self-administered in an uncontrolled manner could result in increased risk, many studies indicate that testosterone applied in a controlled manner is cardio-protective.  Our data at Low T indicates that we have not had any significant cardiac events related to testosterone treatment, even with patients with a prior history of cardiovascular disease."

For More Information Contact:

Dr. William Reilly, M.D.


Low T Center Corporate Offices


1920 East Highway 114


Southlake, Texas 76092


817-417-3800



Reference:

Gallagher v. AbbVie, Inc., et. al.


Case Number 1:14-cv-776


US District Court, Northern District of Illinois


Filed:  2/4/2014




Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes, Journal of Clinical Endocrinology & Metabolism, June 2010, Vol. 95(6):2536–2559      




Trends in Androgen Prescribing in the United States


JAMA, August 2013




Testosterone and Cardioprotection Against Myocardial Ischemia, Cardiovascular & Hematological Disorders-Drug Targets, 2007 Jun;7(2):119-25, PMID: 17584046

SOURCE Low T Center

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Interoute has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Interoute is the owner operator of Europe's largest network and a global cloud services platform, which encompasses over 70,000 km of lit fiber, 15 data centers, 17 virtual data centers and 33 colocation centers, with connections to 195 additional partner data centers. Our full-service Unifie...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs ofte...
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search and...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
We all know that end users experience the internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices - not doing so will be a path to eventual ...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
While presenting own advanced Robo-Advisory Platform, Michał Różański, Managing Partner at EARP and CEO at Empirica, will illustrate the most important issues of building tailored FinTech software in his session at 20th Cloud Expo. He will share experiences we have gained for over 6 years of developing solutions for financial institutions and FinTech companies, including robo-advisors. We welcome all FinTech innovators interested in how properly implemented technology can move their businesses f...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and valu...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...